Haptoglobin study in myasthenia gravis

Arquivos de Neuro-Psiquiatria

Leonardo H. Mendonça Oliveira²  Marcondes C. França Jr¹  Anamarli Nucci¹  Denise Madureira De Oliveira¹  Elza Myiuki Kimura¹  Maria De Fátima Sonati¹ 

[1] ,Campinas State University Faculty of Medical Sciences Departments of NeurologySão Paulo SP ,Brazil

关键词: haptoglobin;    acute phase response;    myasthenia gravis;    immune disorders;    haptoglobina;    resposta de fase aguda;    miastenia grave;    doença autoimune;   

DOI  :  10.1590/S0004-282X2008000200017

来源: SciELO

【 摘 要 】

OBJECTIVE: A cross-sectional study of haptoglobin (Hp) in myasthenia gravis (MG) was designed, with the objective to identify its values and correlate them with different disease status. METHOD: 46 patients were enrolled in the study, all having disease severity established according to the quantitative myasthenia gravis strength scores (QMGSS). Based on the functional scale determined by Myasthenia Gravis Foundation of America (MGFA) recommendations, patients were classified as having: complete stable remission (CSR; n=10); minimal manifestations-0 (MM0; n=6), minimal manifestations-1 (MM1; n=4); pharmacological remission (PR; n=6). Two other groups participated: thymomatous patients (T; n=10) and patients without imunosuppression or thymectomy, until the assessment for Hp (WIT; n=10). Hp dosage was done by immunonephelometry, blindly to clinical data. Student's t-test, Anova test and linear regression were employed for statistical analyses. RESULTS: Statistically significant differences occurred between CSR+MM0xWIT groups (86.62x157.57, p<0.001) and PR+MM1xWIT groups (73.93x157.57, p<0.001). Linear regression showed correlation between Hp levels and QMGSS (r=0.759, p<0.001). CONCLUSION: Our results suggest that Hp may be useful in clinical practice as a disease severity marker in MG.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License